EXTON, Pa., April 25, 2013 /PRNewswire/ -- ViroPharma
Incorporated's (Nasdaq: VPHM) first quarter financial results for
2013 are expected to be released on Wednesday, May 1, 2013 before the open of the
U.S. financial markets.
The company will host a conference call and live audio webcast
at 9:00 a.m. Eastern Time on the same
day. During the conference call, ViroPharma management will
discuss the 2013 first quarter financial results, review clinical
data and provide development program updates along with other
business.
The press release and the live webcast of the conference call
will be accessible via ViroPharma's corporate website at
http://www.viropharma.com. An audio archive will be available
at the same address until May 15,
2013. To participate in the conference call, please dial
(800) 874-4559 (domestic) and (302) 607-2019 (international).
After placing the call, please tell the operator you wish to join
the ViroPharma investor conference call.
About ViroPharma Incorporated
ViroPharma
Incorporated is an international biopharmaceutical company
committed to developing and commercializing novel solutions for
physician specialists to address unmet medical needs of patients
living with diseases that have few if any clinical therapeutic
options. ViroPharma is developing a portfolio of therapeutics
for rare and Orphan diseases including C1 esterase inhibitor
deficiency, cytomegalovirus (CMV), Friedreich's Ataxia,
eosinophilic esophagitis (EoE) and adrenal insufficiency. Our goal
is to provide rewarding careers to employees, to create new
standards of care in the way serious diseases are treated, and to
build international partnerships with the patients, advocates, and
health care professionals we serve. ViroPharma's commercial
products address diseases including hereditary angioedema (HAE),
seizures in children and adolescents, adrenal insufficiency and
C. difficile-associated diarrhea (CDAD). For full U.S.
prescribing information on our products, please download the
package inserts at http://www.viropharma.com/Products.aspx; the
prescribing information for other countries can be found at
www.viropharma.com.
ViroPharma routinely posts information, including press
releases, which may be important to investors in the investor
relations and media sections of our company's web site,
www.viropharma.com. The company encourages investors to consult
these sections for more information on ViroPharma and our
business.
SOURCE ViroPharma Incorporated